Where does Novocure GMBH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novocure GMBH ranks #2,882 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novocure GMBH hold?

Novocure GMBH holds 133 US utility patents granted between 2015 and 2025, spanning 28 technology areas.

What is Novocure GMBH's Innovation Score?

Novocure GMBH has an Innovation Score of 63.9 out of 100 (top 2% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novocure GMBH focus on?

Novocure GMBH's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 101 patents, ranking #33 of 1,943 assignees active in that subclass. Grants appear in 28 CPC subclasses total.

Is Novocure GMBH's patent grant rate increasing or decreasing?

Novocure GMBH's recent grant velocity is +750% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Novocure GMBH's patents?

Novocure GMBH's patents average 13.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novocure GMBH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novocure GMBH

USPTO PatentsView assignee record - 133 granted patents across 28 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novocure ranks #2,882 of 49,997 tracked US assignees by granted-patent volume, with 133 patents across 28 technology areas.

#2,882
of 49,997 US assignees by volume: Top 2%
by Innovation Score (63.9/100): 13.7
avg claims per patent: +750%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2882 · Foreign Corporation #2,882 · 133 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MID 133 grants
TOP-DECILE #2,882/49,997
PHOTO-FINISH Eneos
CPC-FOCUS A61N · 28 areas
INNOV-STRONG 63.9/100
CLAIMS-RICH 13.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +750% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eneos Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novocure’s 63.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.9 pts (26%) Velocity 20.0 pts (31%) Breadth 18.7 pts (29%) Claim depth 8.2 pts (13%)

Qualcomm Incorporated · highest

85
Boston Dynamics · near

64
Cree · near

64
Novocure · this assignee

64
Shenzhen TCL NEW… · near

64
Gambro Lundia AB · near

64
3D Lighting… · lowest

7

What this shows Novocure's Innovation Score is 63.9/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novocure?

Each dot is one of Novocure’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novocure’s own 13.7 claims/patent is ABOVE the 10.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Novocure vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novocure's grants concentrate

Novocure GMBH is a focused PatentsView assignee: 28 CPC subclasses with 75.9% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2024 (39 grants) versus a trough of 1 in 2016. By volume, Novocure sits between Eneos Corporation and Bottega Veneta S.R.L..

Novocure's three-year grant acceleration

Novocure GMBH shows 73 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Eneos

133
Hoya Lens Thailand

133
Hisense Visual Te…

133
Liberty Hardware…

133
Powertech Technol…

133
Research Triangle…

133
Novocure ◀

133
Arcelik Anonim Si…

132
Bottega Veneta S…

132

What this shows Novocure holds 133 patents at rank #2,882, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novocure

By rank, the assignees closest to #2,882 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Novocure's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novocure, neither rank-band nor same-CPC leaders (those blocks stay above). In A61N (Electrotherapy), Novocure ranks #33 of 1,943 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (64 here).

Shenzhen TCL NEW Technology Co., Ltd. 64 Cree, Inc. 64 Boston Dynamics, Inc. 64 Gambro Lundia AB 64

Similar claim depth

Nearest assignees by average claims per patent (13.7 here).

Intervet Inc. 13.7 avg thyssenkrupp Bilstein GmbH 13.7 avg GIESECKE+DEVRIENT Mobile Security GMBH 13.7 avg Universite Grenoble Alpes 13.7 avg

Novocure's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

64 Top 2% higher than 98% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novocure GMBH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	3.0%
2016	1	0.8%
2017	2	1.5%
2018	1	0.8%
2019	2	1.5%
2020	2	1.5%
2021	10	7.5%
2022	18	13.5%
2023	16	12.0%
2024	39	29.3%
2025partial year	38	28.6%

Which technologies does Novocure GMBH patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 101

A61B - DIAGNOSIS; SURGERY; Identification 41

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 20

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 19

G06T - Image Data Processing OR Generation, IN General 14

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 8

G06F - Electric Digital Data Processing 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

G01R - Measuring Electric VARIABLES; Measuring Magnetic Variables 4

H02M - Apparatus FOR Conversion Between AC AND AC, Between AC AND DC, OR Between DC AND DC, AND FOR USE With Mains OR Similar Power Supply SYSTEMS; Conversion OF DC OR AC Input Power Into Surge Output POWER; Control OR Regulation Thereof 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 3

G16Z - Information AND Communication Technology [ICT] Specially Adapted FOR Specific Application Fields, NOT Otherwise Provided FOR 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

A61D - Veterinary Instruments, Implements, Tools, OR Methods 2

Top 15 of 28 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novocure GMBH's patent record in context - here's where to go next.

Novocure GMBH's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 75.9% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #2,882 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novocure GMBH against Eneos Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 63.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.